William (Bill) Larkins has more than 23 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Bill was vice president and general manager of Bedford Laboratories, Inc., where he oversaw a portfolio of more than 100 registered generic injectable products. Previously, he was senior director of product development at Amylin Pharmaceuticals Inc., where he managed development activities for proprietary peptide and protein injectable products. Bill also held positions at Novartis, ESI-Lederle, Barr Laboratories, Inc. and Schein Pharmaceutical, Inc. He began his career as an analytical research chemist. Bill received a doctorate degree in analytical chemistry from The Ohio State University and a bachelor’s degree in chemistry from Purdue University.
sterile injectable generic
Solving formulation and
Writing and publishing
We are Growing.
Founded in 2005, Custopharm has steadily grown to develop more than 30 products
and serve more than 100 organizations across the pharmaceutical industry. In 2015
we partnered with Water Street Healthcare Partners, a strategic investor with extensive
pharmaceutical expertise, to accelerate Custopharm's growth. Since then, we have
enhanced our Regulatory Services team to better support our partners, and augmented
our scientific team to develop more complex pharmaceutical products. With many new
products in development and new opportunities on the horizon, we expect to double
in size and commercialize our own products within the next year.
Our goal is to become a US leader in
generic injectable products. Together with
Water Street, we are investing heavily to expand
our operations, enhance our scientific
personnel, and to pursue new partnerships and
product acquisitions. We are confident that
Custopharm will dramatically increase its role in
bringing important new generic injectable
products to market.
Custopharm has assembled a highly experienced team of
industry executives to lead and grow our company. Our executive
team has deep expertise in sterile injectable pharmaceutical
products and a strong track record of success.
William Larkins, PhD, Chief Executive Officer and Director
Al Heller, Chairman
Al Heller is the former president and CEO of American Pharmaceutical Partners Inc. (APPI), a leading manufacturer of multi-source and branded injectable pharmaceutical products. He also was senior vice president and president of Global Renal Operations for Baxter International, where he led global operations for the Renal and Transfusion Therapies divisions, global manufacturing and the Office of the Chief Scientific Officer. Al began his career at G.D. Searle. During his 23 years with the company, he was promoted to numerous positions, including co-president and COO, and executive vice president and president of Searle Operations. Al currently serves as an operating partner with Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry. He received his bachelor’s degree from the University of Illinois, Chicago and his master’s degree in business administration from DePaul University.
Dan Robins, PhD, Director
Dan Robins is former vice president of global development for Mylan, where he was responsible for injectable products. His former business, Bioniche Pharma, where he led research and development in Ireland, was acquired by Mylan in 2010. Prior to Bioniche Pharma, Dan was vice president of product development for Abraxis BioScience (formerly American Pharmaceutical Partners Inc.) He also held leadership positions at Barr Laboratories, Inc. and scientific roles at Schering-Plough Research Institute, Mallinckrodt Veterinary and Pentech Pharmaceuticals. Dan received master’s and doctorate degrees in chemistry from The Ohio State University and his master’s degree in business administration from New York University. He earned his bachelor’s degree from LaSalle University.
Peter Strothman, Director
Peter Strothman has spent his career investing in the healthcare and private equity industries. He invests and creates value in companies specializing in life sciences, specialty pharmaceutical products and services, and general healthcare products and outsourced services. As a partner with Water Street, Peter has built a leading group of pharmaceutical companies. Prior to joining Water Street, Peter was a principal with JLL Partners, where he focused exclusively on healthcare investments. He began his career in the Global Mergers and Acquisitions group of Lehman Brothers. Peter received a bachelor’s degree in economics from Harvard University.
George Zorich, Director
George Zorich has more than 30 years of pharmaceutical industry experience. Most recently, he served as chief executive officer of Agilis Biotherapeutics, a company focused on developing a cure for Friedreich’s ataxia. Previously, George was president of Bioniche Pharmaceuticals, a manufacturer of branded and generic injectable products that was sold to Mylan Pharmaceuticals. George also was president of Sabex-USA, which was sold to Sandoz, where he led the Sandoz U.S. injectable business. Prior to that, he was president of GIV, which was the largest distributor of vaccines to physician offices. George also held executive positions at Fujisawa (now Astellas), Akorn Pharmaceuticals, Roxane Laboratories and Eli Lilly and Company. He is a board member of the American Society of HealthSystem Pharmacists Foundation and serves on the University of Wisconsin School of Pharmacy Board of Visitors. George received his pharmacy degree from the University of Wisconsin.
We are currently recruiting for a number of career opportunities: If you are interested in becoming part of an entrepreneurial, growing organization, please check out our jobs board to submit your resume.
Custopharm is actively pursuing new product and partnership opportunities.
We are looking to acquire sterile injectable products, strategically partner with
development and manufacturing companies, and provide enhanced support
for our regulatory services partners.
If you are interested in opportunities to partner with Custopharm,
please click here to submit your contact information.
Custopharm Acquires Two ANDA Pharmaceutical Products from Perrigo
CARLSBAD, Calif. – January 4, 2017 – Custopharm, Inc., a U.S. leader in generic injectable products, announced today that it has acquired two paragraph IV abbreviated new drug application (ANDA) products from Perrigo Company plc. The company has attained full-ownership rights to acetaminophen injection (“acetaminophen”) and testosterone undecanoate injection (“testosterone”). Acetaminophen is indicated for the management of mild to moderate pain and reduction of fever in the clinical setting. Testosterone is indicated for testosterone replacement therapy in adult males. “Both of these products are a tremendous fit with Custopharm’s already diverse offering of specialized and high barrier generic pharmaceutical products,” said Dr. William Larkins, chief executive officer, Custopharm. “Our team is excited to acquire these products and begin preparations to bring lower-cost alternatives to these product categories.” Custopharm has developed more than 30 pharmaceutical products over the past ten years. In 2015, the company partnered with Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry, to invest in and expand its capabilities. In the past year, the company has more than doubled its laboratory capacity and team of analytical and formulation scientists and technology transfer process engineers. Custopharm plans to market the acetaminophen and testosterone products under its new commercial business arm, Leucadia Pharmaceuticals. The company is pursuing new opportunities to collaborate with pharmaceutical and biotechnology companies and expand its product portfolio.